12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Provenge sipuleucel-T regulatory update

EMA's CHMP issued a positive opinion recommending approval of Provenge sipuleucel-T from Dendreon to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (CRPC) in adults when chemotherapy is not yet clinically...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >